blog

Faculty of 1000 Oncology Section Head Matti Aapro is a medical oncologist based at the Clinique de Genolier in Switzerland. In this video, he highlights a couple of important presentations at the 2011 European Multidisciplinary Cancer Congress in Stockholm.

The first is about prostate cancer bone metastases and how radioactive compounds can not only provide pain relief but improve survival. The second, which will “change some of our treatment approaches” for breast cancer, concerns Afinitor from Novartis (everolimus). In combination with the oestrogen-blocker exemestane, Afinitor drastically increases progression-free survival. Matti says that if these data are confirmed, and if this progression-free advantage translates to a survival advantage, “we will have an important new approach to the treatment of hormone-resistant breast cancer.”